You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
分析師:新秀麗、比亞迪電子和藥明康德有望被納入恆生指數
格隆匯11月17日|恆生指數公司今日盤後將宣佈第三季度恆生指數系列檢討結果,有分析師稱因指數中醫療保健股的代表性不足,預計在週五的季檢審查中會加入更多的醫療保健股和小型盈利股。 數據分析公司Periscope Analytics在一份報告中稱,箱包製造商新秀麗(1910.HK)、手機零部件製造商比亞迪電子(0285.HK)和製藥公司藥明康德有可能被納入恆生指數。 彭博智庫認爲再鼎醫藥(9688.HK)、金斯瑞生物科技(1548.HK)、信達生物(1801.HK)等生物製藥公司有可能被納入恆生指數。 此次調整是爲了逐步將恆生指數擴大到100個成員,並使股市的代表性更加均衡。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account